Panel Discussion: Reducing Non-Responsiveness of RAS-Targeted Therapies by Delving into Mutation & Tissue Specific Impacts to Improve Drug Efficac
• Uncovering factors within the tumor microenvironment which may result in non-responsiveness to
RAS-targeted therapies
• How do tissue specific interactions influence efficacy of RAS-targeting drugs?
• How do you successfully overcome or delay resistance to RAS-targeting therapies?